Questions and Answers
What is the generic name for Dornase?
What is the trade name for Dornase?
What classification does Dornase belong to?
Mucolytic
What is the action of Dornase?
Signup and view all the answers
What is the dose of Dornase?
Signup and view all the answers
The solution of Dornase should be stored at room temperature.
Signup and view all the answers
Dornase should not be mixed with other medications.
Signup and view all the answers
What are the approved nebulizers for Dornase?
Signup and view all the answers
Study Notes
Dornase Alfa Overview
- Generic Name: Dornase Alfa is the generic name for the medication used in cystic fibrosis treatment.
- Trade Name: The trade name for Dornase Alfa is Pulmozyme.
Classification and Action
- Classification: Dornase Alfa falls under the mucolytic category, which refers to drugs that thin mucus.
- Mechanism of Action: The enzyme works by digesting DNA in the infected sputum, helping to alleviate respiratory issues associated with cystic fibrosis.
Dosage and Administration
- Dose Information: Administered via an ampule containing 2.5 mg in 2.5 ml of a clear, colorless solution (Qd - once daily).
Storage Requirements
- Storage Guidelines: The solution must be refrigerated and should be protected from light to maintain efficacy. Any medication left at room temperature or displaying discoloration should be discarded.
Precautions
- Medication Mixing: Dornase Alfa should not be mixed with other medications to avoid interactions.
Equipment
- Approved Nebulizers: Recommended for use with PARI LC (reusable) nebulizers when paired with the PARI PRO NEB compressor.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
This quiz provides an overview of Dornase Alfa, a mucolytic medication used in treating cystic fibrosis. It covers its classification, mechanism of action, dosage, administration guidelines, and storage requirements. Test your knowledge on the specifics of this important therapeutic agent.
